Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
for Chronic Spontaneous Urticaria
28 locations incl. Birmingham
Sponsor: Celldex Therapeutics
Sex: All·Age: 18+
Code: NCT07256392·Phase 3·Enrolling By Invitation·Listed Dec 2025